Worldwide Cell and Gene Therapy Bioassay Services Industry to 2030 - Featuring CCRM, Nexelis and Pacific BioLabs Among Others
22 mars 2022 06h48 HE
|
Research and Markets
Dublin, March 22, 2022 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Bioassay Services Market by Type of Therapy, Therapeutic Area, Scale of Operation and Geography: Industry Trends and Global...
Global Gene Editing Beyond CRISPR Market (2022 to 2035) - Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies
22 mars 2022 06h13 HE
|
Research and Markets
Dublin, March 22, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing beyond CRISPR Market: Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies:...
Global Genomics Market Forecast to Register Compound Annual Growth of 18.2% to Reach $63.50 Billion in 2026
10 mars 2022 05h08 HE
|
Research and Markets
Dublin, March 10, 2022 (GLOBE NEWSWIRE) -- The "Genomics Global Market Report 2022, By Product Type, By Process, By End User" report has been added to ResearchAndMarkets.com's offering. The global...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
09 mars 2022 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Animal Model Market revenue to cross $30.6 billion by 2028, Says Global Market Insights Inc.
08 mars 2022 05h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, March 08, 2022 (GLOBE NEWSWIRE) -- The animal model market value is projected to surpass USD 30.6 billion by 2028, according to a new research report by Global Market...
Yield10 Bioscience Field Test Results Show Seed Oil Content Increase in Camelina and Canola
01 mars 2022 08h30 HE
|
Yield10 Bioscience, Inc.
WOBURN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that 2021 field test...
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
28 févr. 2022 16h01 HE
|
Intellia Therapeutics, Inc.
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions...
Insights on the Cell and Gene Therapy Global Market to 2026 - by Therapy Type, Product, Application and Region
23 févr. 2022 05h13 HE
|
Research and Markets
Dublin, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Market 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global market for cell and gene...
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
17 févr. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Fourth quarter and full-year 2021 financial results – February 24, at 8:00 a.m. ETUpdated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR)...
Global CRISPR Market & Competition Landscape 2021-2028 Featuring Profiles of Integrated DNA Technologies, Intellia Therapeutics, Horizon Discovery Group, and Precision Biosciences Among Others
04 févr. 2022 05h38 HE
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is anticipated to display growth...